U.S. Markets closed
LISTEN

Schultz: Businesses need to do more to help people

Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
113.80+0.88 (+0.78%)
At close: 4:00PM EDT
People also watch
BMRNSGENACORACADALXN
Full screen
Previous Close112.92
Open111.14
Bid114.00 x 100
Ask116.40 x 200
Day's Range110.60 - 118.40
52 Week Range31.38 - 118.40
Volume2,339,648
Avg. Volume1,207,464
Market Cap10.44B
Beta3.21
PE Ratio (TTM)-22.21
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal18 hours ago

    [$$] Alnylam's New Medicine To Enter Pricing Debate

    Alnylam Pharmaceuticals Inc. will seek approval for a drug treating a rare disease. Its challenge: launching a pricey product amid growing debate about how to fairly value breakthrough medications.

  • Alnylam Is Entering 'New Chapter,' But Ionis Still Has A Chance
    Investor's Business Dailyyesterday

    Alnylam Is Entering 'New Chapter,' But Ionis Still Has A Chance

    Alnylam could enter a new chapter in 2018 as it transitions into a commercial-stage company, an analyst said Thursday.

  • Barrons.comyesterday

    Alnylam Pharmaceuticals: Bet or Fold?

    When a small drug company’s surges almost 52% in a single day after releasing impressive clinical trial results for a potentially revolutionary class of drugs, should investors cash in or go all in? In the case of Alnylam Pharmaceuticals (ALNY), the answer depends on which sell-side analyst happens to be speaking. Instinet’s Christopher Marai advises investors to “sell on the data.” The strong late-stage study results released yesterday for the company’s Patisiran therapy, a RNAi therapeutic, are already baked into the stock price, which sat almost unchanged today at $113.52 a share.